2019
PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy
Zhang H, Pan B, Wu P, Parajuli N, Rekhter MD, Goldberg AL, Wang X. PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy. Science Advances 2019, 5: eaaw5870. PMID: 31131329, PMCID: PMC6531002, DOI: 10.1126/sciadv.aaw5870.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-Crystallin B ChainAnimalsCyclic AMP-Dependent Protein KinasesCyclic GMP-Dependent Protein KinasesCyclic Nucleotide Phosphodiesterases, Type 1DensitometryEchocardiographyFemaleGenotypeHeart FailureHeart VentriclesHemodynamicsHumansHydrolysisMaleMiceMice, TransgenicMicroscopy, FluorescenceMyocytes, CardiacPhosphorylationProteasome Endopeptidase ComplexProtein DenaturationProtein FoldingProteostasis DeficienciesRats
2018
Inhibition of Type 1 Phosphodiesterse Confers Therapeutic Benefit to Proteinopathy‐based HFpEF in Mice
Zhang H, Rekhter M, Wang X. Inhibition of Type 1 Phosphodiesterse Confers Therapeutic Benefit to Proteinopathy‐based HFpEF in Mice. The FASEB Journal 2018, 32: 903.14-903.14. DOI: 10.1096/fasebj.2018.32.1_supplement.903.14.Peer-Reviewed Original ResearchCardiac ubiquitin-proteasome systemProtein kinase GHeart failureEjection fractionTg micePDE1 inhibitionTherapeutic strategiesUbiquitin-proteasome systemLeft ventricular end-diastolic volumeVentricular end-diastolic volumeKaplan-Meier survival analysisInhibition groupNon-Tg miceLV posterior wallProtein kinase AEnd-diastolic volumeHeart failure casesTreatment of HFPotential therapeutic strategyNew therapeutic strategiesMonths of ageFull-text articlesInsufficiency contributesMortality benefitPharmacological therapy